Short answer
Xencor Inc (XNCR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Xencor Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Press release containing results attached as Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $116.5M vs $21.0M, driven by Alexion and Incyte royalties plus Astellas milestone revenue
- Net income $39.4M, or $0.50 diluted EPS, versus $6.0M loss and $(0.08) EPS in Q3 2025
- XmAb819 showed 45.5% confirmed response rate at 400 mcg/kg IV in advanced ccRCC, supporting potential Phase 3 development
- XmAb819 regulatory engagement planned for 1H27, with potential global randomized Phase 3 initiation by end-2027
- Cash and marketable debt securities $555.7M, with $480M-$500M expected year-end cash and funding projected into 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xencor Inc 8-K filings
Get the next XNCR 8-K as it lands
Follow XNCR for push alerts, or ask the research agent what this filing means.